アルツハイマー治療薬市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、エンドユーザー別、地域別、競合別、2019年～2029年

アルツハイマー治療薬の世界市場は2023年に41億3,000万米ドルと評価され、2029年までのCAGRは7.67%で、予測期間中に目覚ましい成長を遂げると予測されています。

アルツハイマー治療薬市場は、アルツハイマー治療薬の市場開拓、生産、販売に関連する世界の産業を指します。この市場には、この衰弱性疾患の進行を遅らせ、それに伴う症状を管理することを目的とした医薬品からホリスティック療法まで、さまざまな製品が含まれます。同市場は、アルツハイマー病の有病率の増加と効果的な治療薬に対する緊急の必要性により、厳格な研究開発努力が行われていることが特徴です。

アルツハイマー治療薬市場は、人口の高齢化、研究開発投資の増加、技術の進歩など様々な要因により、今後数年間で大きな成長が見込まれています。アルツハイマー病の根本的なメカニズムの解明は大きく進展しており、新規の治療ターゲットや潜在的な治療法の開発につながっています。製薬会社や研究機関は、大きな市場リターンの可能性と効果的な治療法の差し迫った必要性から、新しいアルツハイマー治療薬の開発に多額の投資を行っています。

主な市場促進要因

人口の高齢化

診断技術の向上

新薬の承認

主な市場課題

治験のための患者募集

バイオマーカーの不足

主要市場動向

バイオテクノロジーへの投資

保険適用の拡大

セグメント別洞察

製品タイプ別洞察

エンドユーザーの洞察

地域別インサイト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 アルツハイマー治療薬の世界市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別（コリンエステラーゼ阻害薬｛ドネペジル、ガランタミン、リバスチグミン｝、NMDA受容体拮抗薬、配合剤、パイプライン医薬品）
  • エンドユーザー別（病院薬局、小売薬局、eコマース）
  • 地域別
  • 企業別（2023年）
• 市場マップ

第6章 北米のアルツハイマー治療薬市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のアルツハイマー治療薬市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋地域のアルツハイマー治療薬市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のアルツハイマー治療薬市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのアルツハイマー治療薬市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 製品タイプ別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品上市

第13章 アルツハイマー治療薬の世界市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Eisai Co., Ltd.
• Novartis AG
• AbbVie Inc.（Allergan Plc.）
• Adamas Pharmaceuticals, Inc.
• H. Lundbeck A/S
• Biogen Inc.
• AC Immune SA
• F. Hoffmann La Roche Ltd.
• Daiichi Sankyo Company, Limited
• Johnson Johnson

第16章 戦略的提言

第17章 免責事項

Global Alzheimer's Therapeutics Market was valued at USD 4.13 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.67% through 2029. The Alzheimer's Therapeutics Market refers to the global industry associated with the development, production, and sales of treatments for Alzheimer's disease. It includes a range of products from pharmaceutical drugs to holistic therapies that aim to slow the progression of this debilitating disease and manage the symptoms associated with it. The market is characterized by rigorous research and development efforts, driven by the increasing prevalence of Alzheimer's and the urgent need for effective therapeutics.

The Alzheimer's Therapeutics Market is expected to experience significant growth in the coming years due to various factors such as aging population, increasing investment in research and development, and advancements in technology.This has led to a greater demand for effective treatments and therapeutics. There has been significant progress in understanding the underlying mechanisms of Alzheimer's disease, leading to the development of novel therapeutic targets and potential treatments. Pharmaceutical companies and research institutions have been investing heavily in the development of new Alzheimer's therapeutics, driven by the potential for substantial market returns and the pressing need for effective treatments.

Key Market Drivers

Aging Population

The global demand for Alzheimer's therapeutics is experiencing a substantial increase, primarily driven by the aging population worldwide. As the average age of the global population rises, the prevalence of Alzheimer's disease, a neurodegenerative condition associated with aging, is also on the ascent. The aging demographic, characterized by a higher incidence of Alzheimer's and related dementias, has created an escalating demand for effective therapeutics to address the cognitive decline and memory loss associated with the disease.

Pharmaceutical companies are responding to this growing demand by investing in research and development efforts to discover and develop innovative Alzheimer's therapeutics. The urgency to provide solutions for this demographic shift is underscored by the significant social and economic impact of Alzheimer's disease on individuals, families, and healthcare systems globally. The global market response highlights the pharmaceutical industry's recognition of the pressing need for Alzheimer's therapeutics. As the aging population continues to expand, the demand for effective treatments and interventions to mitigate the impact of Alzheimer's disease is expected to persist, making it a critical focus area for pharmaceutical companies and healthcare stakeholders on a global scale.

Improved Diagnostic Techniques

The global demand for Alzheimer's therapeutics is witnessing a notable upswing, propelled by advancements in improved diagnostic techniques. As diagnostic capabilities for Alzheimer's disease become more sophisticated and reliable, there is a consequential increase in the identification and understanding of the condition at early stages. Early and accurate diagnosis is crucial for effective intervention and management of Alzheimer's disease. The enhanced diagnostic precision not only enables more targeted therapeutic interventions but also facilitates the development of novel therapies aimed at slowing or halting the progression of the disease.

Advanced diagnostic techniques enable the early detection of Alzheimer's disease, even before the onset of clinical symptoms. Early diagnosis allows for timely intervention and treatment initiation, which can potentially slow disease progression and improve patient outcomes. Techniques such as positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarker analysis can detect pathological changes associated with Alzheimer's disease years before symptoms manifest.

Pharmaceutical companies are responding to the growing demand by intensifying research efforts to create therapeutics that align with the nuances of early-stage Alzheimer's. The improved diagnostic techniques contribute to a better understanding of the disease's underlying mechanisms, paving the way for the development of innovative drugs that address specific aspects of Alzheimer's pathology. The global market response underscores the industry's recognition of the interdependence between diagnostic advancements and therapeutic innovation. As diagnostic techniques continue to evolve, the demand for tailored Alzheimer's therapeutics is expected to rise, marking a transformative era in the treatment landscape for this neurodegenerative condition on a global scale.

Approval Of New Drugs

The global demand for Alzheimer's therapeutics is experiencing a notable surge, propelled by the approval of new drugs in the pharmaceutical landscape. As regulatory bodies greenlight novel treatments and therapies for Alzheimer's disease, there is a heightened optimism within the pharmaceutical industry. The approval of new drugs not only expands the available options for patients but also signifies advancements in research and development efforts targeting Alzheimer's pathology. Pharmaceutical companies, encouraged by regulatory approvals, are intensifying their commitment to Alzheimer's therapeutics. The influx of new drugs often brings innovation to the market, with treatments designed to address different aspects of the disease, ranging from symptom management to disease modification.

The robust pipeline of novel therapies targeting various aspects of Alzheimer's pathology is a significant driver of market growth. Pharmaceutical companies are investing heavily in research and development (RD) to identify and develop disease-modifying therapies that target underlying mechanisms such as beta-amyloid and tau protein accumulation, neuroinflammation, and synaptic dysfunction.

The global market response underscores the industry's acknowledgment of the impact that regulatory approvals have on the demand for Alzheimer's therapeutics. As more drugs receive regulatory clearance, the landscape for Alzheimer's treatment is evolving, presenting opportunities for pharmaceutical companies to meet the growing demand for effective interventions globally. The approval of new drugs signifies a step forward in the fight against Alzheimer's, offering hope to patients and fueling the momentum for further research and development initiatives.

Key Market Challenges

Patient Recruitment for Trials

The global demand for Alzheimer's therapeutics is facing a downturn, primarily due to challenges in patient recruitment for clinical trials. Conducting robust clinical trials is essential for the development and approval of new Alzheimer's therapeutics, yet recruitment hurdles have become a significant bottleneck. The intricacies of Alzheimer's trials, including stringent eligibility criteria and the need for long-term commitment, make it challenging to enroll a sufficiently diverse and representative patient population. The slow recruitment process not only delays the timeline for drug development but also affects the overall market dynamics.

Pharmaceutical companies and research organizations are grappling with the impact of insufficient patient recruitment on the advancement of Alzheimer's therapeutics. The constrained pool of participants in clinical trials limits the scope of data collection and the generalizability of study outcomes, hindering the progression of potential treatments. The global market response highlights the critical role of patient recruitment in driving the demand for Alzheimer's therapeutics. As industry stakeholders address these recruitment challenges, finding innovative strategies to engage and retain participants, the demand for effective treatments is expected to rebound, fostering a more conducive environment for the development and approval of Alzheimer's therapeutics on a global scale.

Lack of Biomarkers

The global demand for Alzheimer's therapeutics is encountering a setback due to the lack of reliable biomarkers for the disease. Biomarkers play a crucial role in the early diagnosis, monitoring, and development of targeted therapies for Alzheimer's. However, the current absence of definitive biomarkers poses significant challenges for both research and the pharmaceutical industry. The intricacies of Alzheimer's, coupled with the need for accurate and accessible biomarkers, hamper the ability to precisely identify and track the disease's progression.

The pharmaceutical sector's efforts to develop effective therapeutics for Alzheimer's are impeded by the limited availability of biomarkers that can reliably indicate the disease's presence or progression. Without robust biomarkers, clinical trials face difficulties in accurately assessing treatment efficacy and patient response, hindering the advancement of potential therapies. The global market response underscores the critical need for advancements in biomarker research for Alzheimer's disease. As the industry continues to invest in the discovery of reliable biomarkers, the demand for targeted and effective therapeutics is anticipated to grow, revitalizing the landscape for Alzheimer's treatment on a global scale.

Key Market Trends

Investment in Biotechnology

The global demand for Alzheimer's therapeutics is witnessing a substantial upswing, driven by increased investments in biotechnology. Biotechnological advancements have propelled the discovery and development of innovative therapeutic solutions for Alzheimer's disease. The substantial influx of funding into biotechnology firms specializing in neurodegenerative research is accelerating the progress towards novel treatments and potential breakthroughs in Alzheimer's therapeutics.

Pharmaceutical companies are actively collaborating with biotechnology firms or establishing in-house biotechnology divisions to leverage cutting-edge research and technologies. The investments are directed towards understanding the underlying mechanisms of Alzheimer's, identifying novel drug targets, and developing therapies that can address the complex nature of the disease. The global market response underscores the pivotal role of biotechnology in shaping the landscape of Alzheimer's therapeutics. The substantial investments indicate a collective commitment to advancing scientific understanding and translating that knowledge into effective treatments. As the biotechnology sector continues to make strides in Alzheimer's research, the demand for innovative therapeutics is poised to grow, offering hope to individuals affected by the disease on a global scale.

Wider Insurance Coverage

The global demand for Alzheimer's therapeutics is experiencing a notable increase, propelled by the broader coverage provided by insurance policies. As awareness and understanding of Alzheimer's disease grow, insurance companies are expanding their coverage to encompass a wider range of treatments and medications for individuals affected by the condition. The increased financial support from insurance policies enables patients to access a more comprehensive array of Alzheimer's therapeutics, ranging from conventional drugs to emerging innovative treatments.

This broader insurance coverage has a significant impact on the pharmaceutical industry, encouraging research and development efforts as well as facilitating market access for approved Alzheimer's therapeutics. Patients and healthcare providers benefit from improved affordability, reducing financial barriers to accessing critical medications. The global market response underscores the interconnected relationship between insurance coverage and the demand for Alzheimer's therapeutics. As insurance policies become more inclusive, the demand for these treatments is anticipated to rise, fostering a more accessible and equitable landscape for individuals seeking effective interventions for Alzheimer's disease on a global scale.

Segmental Insights

Product Type Insights

Based on the product type, in the global Alzheimer's therapeutics market, cholinesterase inhibitors, namely donepezil, galantamine, and rivastigmine, currently hold a dominant position. These inhibitors have emerged as frontline medications for the treatment of Alzheimer's disease, owing to their proven efficacy in managing symptoms and slowing down the progression of the disease. By inhibiting the breakdown of acetylcholine, a neurotransmitter involved in memory and learning, these medications help improve cognitive function in individuals with Alzheimer's. It is worth noting that the market landscape is continually evolving, with ongoing research and development efforts leading to the discovery of new drugs and innovative treatment approaches aimed at further enhancing patient outcomes and quality of life.

End User Insights

Based on the end-user segment, in the global Alzheimer's therapeutics market can be categorized into hospital pharmacy, retail pharmacy, and e-commerce. It is the E-commerce sector that is currently witnessing the highest growth in the end-user segments, revolutionizing the way medications are accessed and obtained. With the rise of digital technologies and the ongoing pandemic, more and more people are turning to online platforms for the convenience and accessibility they offer. This shift towards E-commerce is not exclusive to Alzheimer's therapeutics but is observed across the entire spectrum of pharmaceutical products. E-commerce platforms provide a hassle-free experience, allowing individuals to browse and purchase medications from the comfort of their own homes. Moreover, they often offer competitive prices and discounts, making healthcare more affordable and accessible to a wider population.

By leveraging the power of technology, E-commerce platforms have transformed the landscape of the Alzheimer's therapeutics market and the pharmaceutical industry. With their user-friendly interfaces, secure payment options, and efficient delivery systems, they have become the go-to choice for many individuals seeking medications and healthcare products. As we continue to witness advancements in digital healthcare, it is expected that E-commerce will further expand its influence, catering to the evolving needs of patients and driving innovation in the field of Alzheimer's therapeutics.

Regional Insights

In the global Alzheimer's therapeutics market, North America stands out as the dominant region. This is primarily due to the higher prevalence of Alzheimer's disease in the region, as well as the increased awareness and understanding of the disease among healthcare professionals and the general population. Furthermore, North America's advanced healthcare infrastructure plays a crucial role in supporting the development and distribution of Alzheimer's therapeutics, ensuring that patients have access to the latest treatments and care options. With ongoing efforts in research and innovation, the region continues to pave the way in combating this debilitating disease and improving the quality of life for those affected.

Key Market Players

Eisai Co., Ltd.

Novartis AG

AbbVie Inc. (Allergan Plc.)

Adamas Pharmaceuticals, Inc.

H. Lundbeck A/S

Biogen Inc.

AC Immune SA

F. Hoffmann La Roche Ltd.

Daiichi Sankyo Company Limited

Johnson Johnson

Report Scope:

In this report, the Global Alzheimer's Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alzheimer's Therapeutics Market,By Product Type:

• Cholinesterase inhibitors
• NMDA Receptor Antagonist
• Combination Drug
• Pipeline Drugs

Alzheimer's Therapeutics Market,By End User:

• Hospital Pharmacy
• Retail Pharmacy
• E-commerce

Alzheimer's Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alzheimer's Therapeutics Market.

Available Customizations:

Global Alzheimer's Therapeutics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validations
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Global Alzheimer's Therapeutics Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Product Type (Cholinesterase inhibitors {Donepezil, Galantamine, Rivastigmine}, NMDA Receptor Antagonist, Combination Drug, Pipeline Drugs)
  • 5.2.2.By End User (Hospital Pharmacy, Retail Pharmacy, E-commerce)
  • 5.2.3.By Region
  • 5.2.4.By Company (2023)
• 5.3.Market Map

6.North America Alzheimer's Therapeutics Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Product Type
  • 6.2.2.By End User
  • 6.2.3.By Country
• 6.3.North America: Country Analysis
  • 6.3.1.United States Alzheimer's Therapeutics Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Product Type
      • 6.3.1.2.2.By End User
  • 6.3.2.Canada Alzheimer's Therapeutics Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Product Type
      • 6.3.2.2.2.By End User
  • 6.3.3.Mexico Alzheimer's Therapeutics Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Product Type
      • 6.3.3.2.2.By End User

7.Europe Alzheimer's Therapeutics Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Product Type
  • 7.2.2.By End User
  • 7.2.3.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.United Kingdom Alzheimer's Therapeutics Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Product Type
      • 7.3.1.2.2.By End User
  • 7.3.2.Germany Alzheimer's Therapeutics Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Product Type
      • 7.3.2.2.2.By End User
  • 7.3.3.France Alzheimer's Therapeutics Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecasty
      • 7.3.3.2.1.By Product Type
      • 7.3.3.2.2.By End User
  • 7.3.4.Italy Alzheimer's Therapeutics Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Product Type
      • 7.3.4.2.2.By End User
  • 7.3.5.Spain Alzheimer's Therapeutics Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Product Type
      • 7.3.5.2.2.By End User

8.Asia-Pacific Alzheimer's Therapeutics Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Product Type
  • 8.2.2.By End User
  • 8.2.3.By Country
• 8.3.Asia-Pacific: Country Analysis
  • 8.3.1.China Alzheimer's Therapeutics Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Product Type
      • 8.3.1.2.2.By End User
  • 8.3.2.India Alzheimer's Therapeutics Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Product Type
      • 8.3.2.2.2.By End User
  • 8.3.3.Japan Alzheimer's Therapeutics Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Product Type
      • 8.3.3.2.2.By End User
  • 8.3.4.South Korea Alzheimer's Therapeutics Market Outlook
    • 8.3.4.1.Market Size Forecast
      • 8.3.4.1.1.By Value
    • 8.3.4.2.Market Share Forecast
      • 8.3.4.2.1.By Product Type
      • 8.3.4.2.2.By End User
  • 8.3.5.Australia Alzheimer's Therapeutics Market Outlook
    • 8.3.5.1.Market Size Forecast
      • 8.3.5.1.1.By Value
    • 8.3.5.2.Market Share Forecast
      • 8.3.5.2.1.By Product Type
      • 8.3.5.2.2.By End User

9.South America Alzheimer's Therapeutics Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Product Type
  • 9.2.2.By End User
  • 9.2.3.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Alzheimer's Therapeutics Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Product Type
      • 9.3.1.2.2.By End User
  • 9.3.2.Argentina Alzheimer's Therapeutics Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Product Type
      • 9.3.2.2.2.By End User
  • 9.3.3.Colombia Alzheimer's Therapeutics Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Product Type
      • 9.3.3.2.2.By End User

10.Middle East and Africa Alzheimer's Therapeutics Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Product Type
  • 10.2.2.By End User
  • 10.2.3.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Alzheimer's Therapeutics Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Product Type
      • 10.3.1.2.2.By End User
  • 10.3.2.Saudi Arabia Alzheimer's Therapeutics Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Product Type
      • 10.3.2.2.2.By End User
  • 10.3.3.UAE Alzheimer's Therapeutics Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Product Type
      • 10.3.3.2.2.By End User

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Recent Development
• 12.2.Mergers Acquisitions
• 12.3.Product Launches

13.Global Alzheimer's Therapeutics Market: SWOT Analysis

14.Porter's Five Forces Analysis

• 14.1.Competition in the Industry
• 14.2.Potential of New Entrants
• 14.3.Power of Suppliers
• 14.4.Power of Customers
• 14.5.Threat of Substitute Products

15.Competitive Landscape

• 15.1.Eisai Co., Ltd.
  • 15.1.1.Business Overview
  • 15.1.2.Company Snapshot
  • 15.1.3.Products Services
  • 15.1.4.Financials (As Reported)
  • 15.1.5.Recent Developments
  • 15.1.6.Key Personnel Details
  • 15.1.7.SWOT Analysis
• 15.2.Novartis AG
• 15.3.AbbVie Inc. (Allergan Plc.)
• 15.4.Adamas Pharmaceuticals, Inc.
• 15.5.H. Lundbeck A/S
• 15.6.Biogen Inc.
• 15.7.AC Immune SA
• 15.8.F. Hoffmann La Roche Ltd.
• 15.9.Daiichi Sankyo Company, Limited
• 15.10.Johnson Johnson

16.Strategic Recommendations

17.About Us Disclaimer